Abstract:β-lactam antibiotics are the most successful and commonly used antibacterial agents, but the emergence of resistance to these drugs has become a global health threat. The expression of β-lactamase enzymes produced by pathogens, which hydrolyze the amide bond of the β-lactam ring, is the major mechanism for bacterial resistance to β-lactams. In particular, among class A, B, C and D β-lactamases, metallo-β-lactamases (MBLs, class B β-lactamases) are considered crucial contributors to resistance in gram-negative bacteria. To combat β-lactamase-mediated resistance, great efforts have been made to develop β-lactamase inhibitors that restore the activity of β-lactams. Some β-lactamase inhibitors, such as diazabicyclooctanes (DBOs) and boronic acid derivatives, have also been approved by the FDA. Inhibitors used in the clinic can inactivate mostly serine-β-lactamases (SBLs, class A, C, and D β-lactamases) but have not been effective against MBLs until now. In order to develop new inhibitors particularly for MBLs, various attempts have been suggested. Based on structural and mechanical studies of MBL enzymes, several MBL inhibitor candidates, including taniborbactam in phase 3 and xeruborbactam in phase 1, have been introduced in recent years. However, designing potent inhibitors that are effective against all subclasses of MBLs is still extremely challenging. This review summarizes not only the types of β-lactamase and mechanisms by which β-lactam antibiotics are inactivated, but also the research finding on β-lactamase inhibitors targeting these enzymes. These detailed information on β-lactamases and their inhibitors could give valuable information for novel β-lactamase inhibitors design.

Metallo-Beta-Lactamases: Structural Features, Antibiotic Recognition, Inhibition, and Inhibitor Design

Metallo-β-lactamase inhibitors: A continuing challenge for combating antibiotic resistance

Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors

Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects

Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery

&Amp;#946;-Lactamase Inhibitors: an Update

Insights from Modeling the 3D Structure of New Delhi Metallo-Β-lactamse and Its Binding Interactions with Antibiotic Drugs.

Metallo Beta Lactamase Enzymes

Metallo-ß-lactamases: a review

Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria

A common binding mode that may facilitate the design of novel broad-spectrum inhibitors against metallo-β-lactamases

Recent research and development of NDM-1 inhibitors

Metal organic framework-based antibacterial agents and their underlying mechanisms

Structure and mechanism of potent bifunctional β-lactam- and homoserine lactone-degrading enzymes from marine microorganisms

Synthesis and Evaluation of Carbapenem/Metallo-β-Lactamase Inhibitor Conjugates

Design, Synthesis, and Biological Evaluation of New 1H-Imidazole-2-Carboxylic Acid Derivatives as Metallo-β-Lactamase Inhibitors

Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms

Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding

Mechanism-guided strategies for combating antibiotic resistance

Metal binding pharmacophore click-derived discovery of new broad-spectrum metallo-β-lactamase inhibitors

Metallo-β-Lactamase Inhibitors Inspired on Snapshots from the Catalytic Mechanism